CN102971296B - 包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物 - Google Patents

包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物 Download PDF

Info

Publication number
CN102971296B
CN102971296B CN201180032341.1A CN201180032341A CN102971296B CN 102971296 B CN102971296 B CN 102971296B CN 201180032341 A CN201180032341 A CN 201180032341A CN 102971296 B CN102971296 B CN 102971296B
Authority
CN
China
Prior art keywords
compound
cancer
particles
pharmaceutical composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180032341.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102971296A (zh
Inventor
D.S.宾德拉
M.Y.戈克黑尔
C.J.努涅斯
V.W.罗索
G.M.施罗德
A.B.撒克
殷小天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102971296A publication Critical patent/CN102971296A/zh
Application granted granted Critical
Publication of CN102971296B publication Critical patent/CN102971296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180032341.1A 2010-04-30 2011-04-29 包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物 Active CN102971296B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32971010P 2010-04-30 2010-04-30
US61/329,710 2010-04-30
PCT/US2011/034417 WO2011137274A1 (en) 2010-04-30 2011-04-29 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide

Publications (2)

Publication Number Publication Date
CN102971296A CN102971296A (zh) 2013-03-13
CN102971296B true CN102971296B (zh) 2015-11-25

Family

ID=44209564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180032341.1A Active CN102971296B (zh) 2010-04-30 2011-04-29 包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物

Country Status (17)

Country Link
US (2) US8911785B2 (https=)
EP (1) EP2563763B1 (https=)
JP (1) JP5820874B2 (https=)
KR (1) KR101897302B1 (https=)
CN (1) CN102971296B (https=)
DK (1) DK2563763T3 (https=)
ES (1) ES2533075T3 (https=)
HR (1) HRP20150105T1 (https=)
MY (1) MY183769A (https=)
PH (1) PH12012502019A1 (https=)
PL (1) PL2563763T3 (https=)
PT (1) PT2563763E (https=)
RS (1) RS53790B1 (https=)
SG (1) SG184891A1 (https=)
SI (1) SI2563763T1 (https=)
SM (1) SMT201500069B (https=)
WO (1) WO2011137274A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080905B (zh) * 2011-12-22 2016-11-16 生命技术公司 细胞培养基和方法
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
WO2020150307A1 (en) * 2019-01-15 2020-07-23 The Translational Genomics Research Institute Phosphonate conjugates and uses thereof
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058229A1 (en) * 2006-11-08 2008-05-15 Bristol-Myers Squibb Company Pyridinone compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
WO2006118210A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. ジヒドロピリジン系化合物の分解を防止する方法
TR200504775A1 (tr) 2005-11-30 2007-10-22 Esen Beki̇r Kendinden metal takviyeli pvc pencere ve kapı profilleri
PT1808164E (pt) * 2006-01-05 2009-03-17 Teva Pharma Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058229A1 (en) * 2006-11-08 2008-05-15 Bristol-Myers Squibb Company Pyridinone compounds
CN101535264A (zh) * 2006-11-08 2009-09-16 百时美施贵宝公司 吡啶酮化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily;Gretchen M. Schroeder et al.;《J. Med. Chem.》;20090213;第52卷(第5期);1251-1254 *
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs;Teo´filo Vasconcelos et al.;《Drug Discovery Today》;20071231;第12卷(第23/24期);1068-1075 *

Also Published As

Publication number Publication date
ES2533075T3 (es) 2015-04-07
US20150065719A1 (en) 2015-03-05
SG184891A1 (en) 2012-11-29
US8911785B2 (en) 2014-12-16
KR20130100237A (ko) 2013-09-10
US20130039989A1 (en) 2013-02-14
RS53790B1 (sr) 2015-06-30
EP2563763A1 (en) 2013-03-06
PH12012502019A1 (en) 2017-08-18
WO2011137274A1 (en) 2011-11-03
DK2563763T3 (en) 2015-04-07
HK1179260A1 (en) 2013-09-27
KR101897302B1 (ko) 2018-09-11
PT2563763E (pt) 2015-03-31
SI2563763T1 (sl) 2015-03-31
JP5820874B2 (ja) 2015-11-24
EP2563763B1 (en) 2014-12-31
SMT201500069B (it) 2015-05-05
HRP20150105T1 (hr) 2015-03-13
CN102971296A (zh) 2013-03-13
JP2013525455A (ja) 2013-06-20
AU2011245269A1 (en) 2012-12-20
PL2563763T3 (pl) 2015-06-30
US9233948B2 (en) 2016-01-12
MY183769A (en) 2021-03-12

Similar Documents

Publication Publication Date Title
KR102519922B1 (ko) 트리아졸로피리미딘 화합물의 결정질 형태
JP2019163337A (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
TW200911781A (en) Novel crystalline forms of a VEGF-R inhibitor
JP3763414B2 (ja) Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
TW202233625A (zh) Ｆｇｆｒ抑制劑及其製造及使用方法
CN102971296B (zh) 包含n-(4-(2-氨基-3-氯吡啶-4-基氧基)-3-氟苯基)-4-乙氧基-1-(4-氟苯基)-2-氧代-1，2-二氢吡啶-3-羧酰胺的药物组合物
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP6463874B2 (ja) 医学的適用用の３−（１，２，４−トリアゾロ［４，３−ａ］ピリジン−３−イルエチニル）−４−メチル−Ｎ−（４−（（４−メチルピペラジン−１−イル）メチル）−３−トリフルオロメチルフェニル）ベンズアミドの新規な結晶性塩形態
AU2011245269B2 (en) Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
CN112119062B (zh) 化合物晶型、其制备方法、药物组合物以及应用
HK1179260B (en) Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
WO2025107298A1 (zh) 晶体、药物组合物及其制备方法和应用
HK40123031A (zh) 晶体、药物组合物及其制备方法和应用
WO2025085791A1 (en) Crystalline forms of mrtx0902
WO2024067085A1 (zh) 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2024208265A1 (zh) 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型
WO2025007275A1 (zh) [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用
CN119654328A (zh) (S)-7-氧杂-2-氮杂-螺[4.5]癸烷-2-甲酸[7-(3,6-二氢-2H-吡喃-4-基)-4-甲氧基-噻唑并[4,5-c]吡啶-2-基]-酰胺的新型结晶形式及其共晶形式
WO2026044861A1 (zh) 一种pan-KIT激酶抑制剂化合物及其盐的晶型和应用
BR112018071498B1 (pt) Composto, método para prepará-lo, composição e respectivos usos

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant